AVROBIO Inc

NASDAQ AVRO

Download Data

AVROBIO Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: 157.09%

AVROBIO Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is 157.09% for the quarter ending March 31, 2024, a 683.35% change year over year. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • AVROBIO Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2023 was 0.39, a -26.93% change year over year.
  • AVROBIO Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2022 was 0.53, a -45.88% change year over year.
  • AVROBIO Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2021 was 0.98, a 1.66% change year over year.
  • AVROBIO Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2020 was 0.97, a 3.02% change year over year.
NASDAQ: AVRO

AVROBIO Inc

CEO Mr. Geoff MacKay BSc
IPO Date June 21, 2018
Location United States
Headquarters Building 300, Cambridge, MA, United States, 02139
Employees 13
Sector Healthcare
Industry Biotechnology
Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email